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In our review on statins, published in BLL (1) we described the side effects of statins that reduce endogenous production of coenzyme Q10 (Q10). Regarding the side effects of statins, a myopathy marked with muscle pain occurs in patients prescribed high statin dose. This muscle disorder is related to statin inhibition of farnesyl phosphate resulting in the decrease of Q10. Such a decrease was observed both in experimental animals (2) and humans (3). It was suggested that a defi ciency of Q10 in the pancreas could impair bioenergetics, the generation of ATP, and the biosynthesis of insulin (4). In diabetes, CoQ 10 defi ciency may be linked to impaired beta-cell function and the development of insulin resistance (5). Low plasma CoQ 10 concentrations have been negatively correlated with poor glycaemic control and diabetic complications.
More recent studies have shown that statins increased the risk of type 2 diabetes. Large scale meta-analyses of statin trials support the concept of a diabetogenic effect of statins (6) . Recently an increased risk of new onset treated diabetes was found in patients treated with statins (7). Due to aggressive marketing efforts statin use started to increase dramatically. In USA the rate of diabetes gradually increased from 1958 to 1996. Then around 1997 the rate of diabetes suddenly jumps by 500 percent (Fig. 1) . Did current obesity epidemic suddenly increase by 500 percent in 1997? No, but something else happened in the mid to late 1990s to accelerate this trend. Statin use seems to be the most likely suspect. Although it does appear that statins may increase the diabetes, this should not stop diabetics from using of statins, as this small risk is outweighed by the substantial reduction in cardiovascular events. On the other side, caution should be taken in prescribing statins for primary prevention among people at low cardiovascular risk.
